Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial
Authors
- Hao Ding (ORCID: https://orcid.org/0000-0003-3070-7181)
- Houyong Li
- Xicai Sun (ORCID: https://orcid.org/0000-0003-1423-0942)
- Huankang Zhang (ORCID: https://orcid.org/0000-0001-7467-8197)
- Quan Liu (ORCID: https://orcid.org/0000-0002-9036-0290)
- Tian Wang (ORCID: https://orcid.org/0000-0003-4295-5908)
- Dehui Wang (ORCID: https://orcid.org/0000-0003-0346-3193)
- Yufei Yang (ORCID: https://orcid.org/0000-0003-4635-2717)
- Yurong Gu (ORCID: https://orcid.org/0000-0002-9178-8205)
- Wanpeng Li
- Huapeng Yu
- Haoyuan Xu
Institutions
- Fudan University (CN)
- Eye & ENT Hospital of Fudan University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2025-011998
- Citations
- 3
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.54
Funders
- Science and Technology Commission of Shanghai Municipality
- Shanghai Hospital Development Center